Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $792.3K
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| MSG | Ann: Corporate Governance Statement | 20/04/18 | 0 | 85 | |||
|
|||||||
| MSG | Ann: Incorrect Appendix 3Y | 03/04/18 | 4 | 652 | |||
|
|||||||
| MSG | Ann: Change of Director's Interest Notice | 03/04/18 | 0 | 104 | |||
|
|||||||
| MSG | Ann: Half Yearly Report and Accounts | 22:10 | 14 | 2.6K | |||
|
|||||||
| MSG | Ann: Change of Director's Interest Notice | 09/03/18 | 2 | 401 | |||
|
|||||||
| MSG | Ann: Appendix 4C amended | 25/02/18 | 12 | 2.0K | |||
|
|||||||
See All Discussions
ASX News